Nature's Green Potential: Anticancer Properties of Plants of the Euphorbiaceae Family.

Euphorbiaceae family anticancer extracts in vitro in vivo nanoparticles pure compounds

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Dec 2023
Historique:
received: 20 11 2023
revised: 17 12 2023
accepted: 21 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

The number of cancer cases will reach 24 million in 2040, according to the International Agency for Research on Cancer. Current treatments for cancer are not effective and selective for most patients; for this reason, new anticancer drugs need to be developed and researched enough. There are potentially useful drugs for cancer isolated from plants that are being used in the clinic. Available information about phytochemistry, traditional uses, in vitro and in vivo experiments with plants, and pure compounds isolated from the Euphorbiaceae family indicates that this family of plants has the potential to develop anticancer drugs. This review examines selected species from the Euphorbiaceae family and their bioactive compounds that could have potential against different types of cancer cells. It reviews the activity of crude extracts, isolated compounds, and nanoparticles and the potential underlying mechanisms of action.

Identifiants

pubmed: 38201542
pii: cancers16010114
doi: 10.3390/cancers16010114
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Víctor Jiménez-González (V)

Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.

Tomasz Kowalczyk (T)

Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.

Janusz Piekarski (J)

Department of Surgical Oncology, Medical University in Lodz, 93-513 Lodz, Poland.

Janusz Szemraj (J)

Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.

Patricia Rijo (P)

CBIOS-Lusófona University's Research Center for Biosciences and Health Technologies, 1749-024 Lisbon, Portugal.
Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal.

Przemysław Sitarek (P)

Department of Medical Biology, Medical University of Lodz, 90-151 Lodz, Poland.

Classifications MeSH